abbottlaboratories
Key Points Abbott Laboratories reports a solid quarter despite the decline of COVID-related sales.The core business is up 10%, driven by devices and gains in 3 of 4 segments.This dividend is reliable and can be expected to grow.5 stocks we like better than Abbott LaboratoriesIt is no surprise that Abbott Laboratories (NYSE:ABT) produce a solid quarter. Med-tech companies like Intuitive Surgical (NASDAQ: ISRG), Boston Scientific (NYSE: BSX) and DexCom (NASDAQ: DXCM) have seen an increase in analyst interest driven by results and outlook. What is surprising is that Abbott Laboratories’ device gr...
ValueWalk
The institutions are buying Johnson & Johnson and Abbot Laboratories.The two are Dividend Kings with the power to continue raising their dividends for years.One is ready to rebound, the other to continue leading the broad market higher.If you are looking for a healthy dividend in the healthcare sector, look no further than Abbott Laboratories (NYSE:ABT). These companies are among the highest-quality Dividend Kings not just in their industry; they both have the power to continue raising their dividends long into the future. Add in fact the institutions are buying them and there is an opportunit...
ValueWalk
Abbott Laboratories Falls On Better Than Expected ResultsAbbott Laboratories (NYSE:ABT) is not in danger of losing its business but we have some concerns its share price could fall. Not only is it a highly-valued stock compared to peers but its current revenue and earnings are based largely on COVID-19. The core business is still there but COVID-19 testing accounted for 27% of net revenue and those sales are expected to plummet in the coming quarters. Assuming, of course, that COVID testing becomes less of a pressing need but the fact remains, Abbott Laboratories is trading at over 24X its ear...
ValueWalk
CNBC transcript: Abbott Laboratories (NYSE:ABT) President & CEO Robert Ford speaks with Jim Cramer live during CNBC‘s Healthy Returns Summit today Q1 2021 hedge fund letters, conferences and more WHEN: Today, Tuesday, May 11 WHERE: CNBC’s “Healthy Returns Summit: New Era of Innovation” Interview With Abbott CEO Robert FordTYLER MATHISEN: Testing is going to be critical to the success of reopening. I'll tell you just a quick story. I took my son and his best friend to a Yankee game, along with my wife last Friday night, and the whole key of it was testing. You had to show proof that you were te...
ValueWalk
ValueWalk
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら